AU2019333181A1 - Chimeric oncolytic herpesvirus that stimulate an antitumor immune response - Google Patents

Chimeric oncolytic herpesvirus that stimulate an antitumor immune response Download PDF

Info

Publication number
AU2019333181A1
AU2019333181A1 AU2019333181A AU2019333181A AU2019333181A1 AU 2019333181 A1 AU2019333181 A1 AU 2019333181A1 AU 2019333181 A AU2019333181 A AU 2019333181A AU 2019333181 A AU2019333181 A AU 2019333181A AU 2019333181 A1 AU2019333181 A1 AU 2019333181A1
Authority
AU
Australia
Prior art keywords
cancer
tumor
nucleic acid
herpesvirus
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019333181A
Other languages
English (en)
Inventor
Kevin A. Cassady
Justin C. ROTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Institute at Nationwide Childrens Hospital
Original Assignee
Research Institute at Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Institute at Nationwide Childrens Hospital filed Critical Research Institute at Nationwide Childrens Hospital
Publication of AU2019333181A1 publication Critical patent/AU2019333181A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019333181A 2018-08-31 2019-08-30 Chimeric oncolytic herpesvirus that stimulate an antitumor immune response Pending AU2019333181A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725809P 2018-08-31 2018-08-31
US62/725,809 2018-08-31
PCT/US2019/049047 WO2020047398A1 (en) 2018-08-31 2019-08-30 Chimeric oncolytic herpesvirus that stimulate an antitumor immune response

Publications (1)

Publication Number Publication Date
AU2019333181A1 true AU2019333181A1 (en) 2021-03-18

Family

ID=69643794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019333181A Pending AU2019333181A1 (en) 2018-08-31 2019-08-30 Chimeric oncolytic herpesvirus that stimulate an antitumor immune response

Country Status (10)

Country Link
EP (1) EP3843761A4 (ja)
JP (1) JP2021534786A (ja)
KR (1) KR20210053923A (ja)
CN (1) CN113396217A (ja)
AU (1) AU2019333181A1 (ja)
BR (1) BR112021003807A8 (ja)
CA (1) CA3110406A1 (ja)
IL (1) IL281085A (ja)
SG (1) SG11202101829UA (ja)
WO (1) WO2020047398A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096996A2 (en) 2021-11-24 2023-06-01 Research Institute At Nationwide Children's Hospital Chimeric hsv expressing hil21 to boost anti-tumor immune activity
WO2023235377A1 (en) * 2022-05-31 2023-12-07 The Research Institute At Nationwide Children's Hospital Il-27 expressing oncolytic viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO2007005876A2 (en) * 2005-07-01 2007-01-11 The Uab Research Foundation Chimeric herpes viruses and uses thereof

Also Published As

Publication number Publication date
JP2021534786A (ja) 2021-12-16
WO2020047398A1 (en) 2020-03-05
SG11202101829UA (en) 2021-03-30
KR20210053923A (ko) 2021-05-12
EP3843761A4 (en) 2022-06-08
IL281085A (en) 2021-04-29
CA3110406A1 (en) 2020-03-05
WO2020047398A9 (en) 2020-04-30
EP3843761A1 (en) 2021-07-07
CN113396217A (zh) 2021-09-14
BR112021003807A2 (pt) 2021-05-18
BR112021003807A8 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
Lim et al. Current state of immunotherapy for glioblastoma
Ma et al. The emerging field of oncolytic virus-based cancer immunotherapy
Guo et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives
ES2831080T3 (es) Virus oncolítico modificado
CN109152815B (zh) 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
KR102389240B1 (ko) 면역-종양 살상 요법
BR112019013215A2 (pt) vírus oncolítico, composição farmacêutica, produto de fabricação, método para tratar câncer e uso
JP2021527694A (ja) 腫瘍溶解性ウイルスを用いた処置
CN107847534B (zh) Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
BR112015021414B1 (pt) vírus da doença newcastle e seus usos
AU2017274540B2 (en) Compositions and methods for tumor vaccination using prostate cancer-associated antigens
Delitto et al. Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
BR112015022367B1 (pt) Vacina, molécula de ácido nucleico, e, molécula de aminoácido
Ishizaki et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model
JP2019506428A (ja) ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
US20200179447A1 (en) Autologous irradiated whole cell tumor vaccines lentivirally engineered to express cd80, il-15 and il-15 receptor alpha
US20220233666A1 (en) Cancer vaccine
CA2980622A1 (en) Agents and compositions for eliciting an immune response
AU2019333181A1 (en) Chimeric oncolytic herpesvirus that stimulate an antitumor immune response
US20220088183A1 (en) Chimeric oncolytic herpesvirus that stimulates an antitumor immune response
Wang et al. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Derani Combining Radiation and Oncolytic Measles Virus for the Treatment of Refractory Tumors
US20220211814A1 (en) Il-36 cytokine expressing oncolytic viruses for treating cancer
Sun et al. IMMU-35. TREM2 RESTRAINS ANTI-TUMOR CELL ACTIVITY OF MYELOID CELLS IN GLIOBLASTOMA
Saenz et al. P03. 01 Development of a multi-tumour antigen vaccine for hard-to-treat cancers